A 1 -A 2 9 8 modeled for a time horizon of 35-40 years or for a lifetime to demonstrate cost effectiveness. CONCLUSIONS: This analysis shows the range, variability, and methods used for calculation of ICER values for these high budget impact drugs and provides lessons for executives and policy makers.
OBJECTIVES:
Economic evaluations of health technologies have long relied on one-way sensitivity analysis (SA) to examine the impact of parameter uncertainty on modeling outcomes. Traditionally, this impact has been measured and ranked based on absolute changes in the incremental costeffectiveness ratio (ICER) across plausible parameter values and presented in a tornado diagram. This format does not adequately identify or prioritize parameters where the range of uncertainty causes the ICER to change quadrants in the cost-effectiveness (CE) plane. However, these quadrant changes, which represent fundamental changes to the CE conclusion, are arguably more meaningful than changes in the ICER within a quadrant. This research illustrates a novel approach to presenting one-way SA results that focuses on identifying parameters with the greatest potential to change the overall CE conclusion rather than narrowly focusing on changes to the ICER. METHODS: We developed a comprehensive algorithm for ranking the parameters varied in a one-way SA. Broadly, we first prioritize parameters with the potential to qualitatively change the CE conclusion and then rank parameters based on quantitative changes to modeling outcomes. Changes to the CE conclusion are identified based on quadrant changes in the CE plane, and parameters are categorized as having the potential to change the conclusion both positively and negatively, only positively, only negatively, or not at all. Within these categories, a secondary ranking based on costs and health outcomes is used. Furthermore, visualization techniques anchored in the CE plane help assess whether conclusion changes are due primarily to changes in health, changes in costs, or both. RESULTS: This research demonstrates that the conclusions-based ranking algorithm works in more general settings than the traditional tornado diagram format. CONCLUSIONS: The conclusions-based approach is a powerful method that provides a more complete picture of the impact of parameter uncertainty in economic evaluations.
PRM42 IDENTIFYING ACCURATE PATIENT-BASED HEALTH AND SOCIAL CARE COSTS OF OLDER PEOPLE FOR TRIAL-BASED ECONOMIC EVALUATION: IS IT REALLY WORTH IT?
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OBJECTIVES: Acute Medical Units (AMUs) identify individuals requiring inpatient care and those who can be discharged. However, readmission rates for older people in the year following AMU discharge are high. We aimed to identify patient-based health and social-care costs of a cohort of older (70+) people discharged home from AMU within 72 hours. METHODS: Although resource-use data from social and health care sectors in England is available electronically, there is little systems-linkage so data were obtained from each sector separately. Hospitalisation and social care data were collected retrospectively for 644 patients for three months post-AMU discharge using patient administration systems. In a subset (n=456), further approvals were gained for general practices, ambulance services, intermediate and mental health care. Of 118 general practices serving our cohort, data were obtained from 48 (250/456 participants). Seventeen were not covered by our approvals, and, despite an expert and dedicated team, 53 declined access or did not respond. RESULTS: We obtained data on hospitalisations for all participants, and "full" costs for 250 participants. Mean (95% CI, median, range) total cost for this subgroup was £2006 (1642-2470, 0, 0-23612). Secondary care constituted 76.2% costs. Contribution from other sectors was: primary care (10.9%), ambulance service (0.7%), intermediate care (0.1%), mental health care (2.1%) and social care (10.0%) The top 10% participants accounted for 50% of overall cost. CONCLUSIONS: This study was resource-intensive due to: complex approvals and access requirements; geographical dispersion of participants and data sources; different recording systems; varying data quality; different care definitions across geographical sites; with manual data extraction often required. Care of older people is generally moving from secondary care to primary health care and social care, so the costs of other sectors will increase in the future. There is clearly a need to improve access and system interoperability and streamline methods for obtaining these costs. 
PRM43 THE LOWER AND UPPER LIMITS OF AN INCREMENTAL COST-EFFECTIVENESS RATIO ASSOCIATED WITH THE EFFICIENCY FRONTIER: A CASE OF HIV/AIDS PREVENTION AND TREATMENT

OBJECTIVES:
To validate a theoretical method, using a case study of efficiency frontier analysis for HIV/AIDS prevention and treatment, for quantifying lower and upper limits of the ICER configurated as a slope of the connected lines on the efficiency frontier, whose research poster in theory was presented at the ISPOR Dublin 2007. METHODS: A validation study was conducted based on the evidence published on the Journal of Medical Economics as one of the first studies that identified cost-effectiveness variation in efficient frontiers for HIV/AIDS prevention and treatment documented in the database, CostEffectiveness Analysis Registry, at Tufts Medical Center in [2002] [2003] [2004] [2005] [2006] [2007] . RESULTS: Recognizing that there are two types of efficiency frontier represented with a monotonically increasing function of QALY on the Y-axis and Cost on the Xaxis, and also each efficiency frontier is formulated by two regression models: log and square-root models, two types of the mathematical formulae of derivatives were obtained according to each regression model. The formula of derivatives can provide the slope of the tangent on the efficiency frontier curve, given an arbitrary value of cost (or QALY). Therefore, we developed the formula that can provide lower and upper slopes of the two tangents, given an arbitrary ICER slope which is represented by connecting two points on the efficiency frontier curve. The examples of calculations conducted were graphically illustrated according to each regression model. CONCLUSIONS: Through this validation study, we can confirm that an application of our method is theoretically and practically feasible to estimate the lower and upper limits of an ICER arbitrarily given on the efficiency frontier curve. This approach will provide us with more useful information on the question how we could interpret and justify the high value of ICER of new technologies such as molecular-targeted drugs. 
PRM44 BIAS IN RELATIVE ACCURACY METRICS
OBJECTIVES:
Reimbursement to beneficiaries and cost-effectiveness analyses depend on the availability of estimates of billed-charge amounts. In the United States, no single data source is universally accepted; rather, several vendors compile distributions of billed charges. Studies use these estimates interchangeably and there is no preferred metric for characterizing differences in conducting comparisons. Nonetheless, the conventional wisdom suggests that Medicare data tend to underestimate means and other values relative to commercial data. This paper investigates the statistical properties of three metrics used to characterize relative differences between two sources of values. For these metrics, the difference between the tested and reference values is the numerator; the denominators are the tested value (Metric #1), the reference value (#2), or the average of the two (#3). METHODS: Each metric is described; mathematical proofs and simulations demonstrate the types of bias that can be introduced. RESULTS: Two simulations of constructed distributions with identical means, one with small value differences and the other with large value differences, demonstrate that Metrics #1 and #2 would result in opposite inferences. Proofs demonstrate that the expected values of Metrics #1, #2, and #3 respectively, are negative, positive, and zero. The head to head comparison of two billed charge benchmarks finds bias present across all three averages (simple, weighted by claim count, and weighted by claim dollars), although it is most pervasive for the simple average. The sign of the average of Metric #1 is consistently negative, while that for Metric #2 is positive and Metric #3 varies. CONCLUSIONS: When many observations are aggregated to generate an overall average, the choice of metric affects results, often to the point where the choice of one methodology or another can generate diametrically opposite conclusions.
